ATE552257T1 - Positive allosterische chinolizidinon-m1- rezeptormodulatoren - Google Patents

Positive allosterische chinolizidinon-m1- rezeptormodulatoren

Info

Publication number
ATE552257T1
ATE552257T1 AT08839786T AT08839786T ATE552257T1 AT E552257 T1 ATE552257 T1 AT E552257T1 AT 08839786 T AT08839786 T AT 08839786T AT 08839786 T AT08839786 T AT 08839786T AT E552257 T1 ATE552257 T1 AT E552257T1
Authority
AT
Austria
Prior art keywords
positive allosteric
quinolicidinone
receptor modulators
receptor
compounds
Prior art date
Application number
AT08839786T
Other languages
English (en)
Inventor
Scott Kuduk
Ronald Chang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE552257T1 publication Critical patent/ATE552257T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT08839786T 2007-10-18 2008-10-15 Positive allosterische chinolizidinon-m1- rezeptormodulatoren ATE552257T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99942407P 2007-10-18 2007-10-18
PCT/US2008/011752 WO2009051715A1 (en) 2007-10-18 2008-10-15 Quinolizidinone m1 receptor positive allosteric modulators

Publications (1)

Publication Number Publication Date
ATE552257T1 true ATE552257T1 (de) 2012-04-15

Family

ID=40229870

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08839786T ATE552257T1 (de) 2007-10-18 2008-10-15 Positive allosterische chinolizidinon-m1- rezeptormodulatoren

Country Status (7)

Country Link
US (1) US8258135B2 (de)
EP (1) EP2212322B1 (de)
JP (1) JP2011500678A (de)
AT (1) ATE552257T1 (de)
AU (1) AU2008311971A1 (de)
CA (1) CA2700648A1 (de)
WO (1) WO2009051715A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2252151B1 (de) * 2008-02-13 2014-05-14 Merck Sharp & Dohme Corp. Positive allosterische chinolizidinon-m1-rezeptormodulatoren
EP2575454B1 (de) * 2010-05-28 2018-08-29 Merck Sharp & Dohme Corp. Positive allostere naphthalen-carboxamid-m1-rezeptormodulatoren
WO2013129622A1 (ja) 2012-03-02 2013-09-06 武田薬品工業株式会社 複素環化合物およびその用途
EP2921480B1 (de) 2012-11-19 2017-10-11 Takeda Pharmaceutical Company Limited Stickstoffhaltige heterocyclische verbindung
PT3802517T (pt) 2018-06-07 2023-03-20 Idorsia Pharmaceuticals Ltd Derivados de piridinilo substituídos por alcoxi como antagonistas do recetor de lpa1 e a sua utilização no tratamento da fibrose
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
CN111116576A (zh) * 2019-12-01 2020-05-08 北京师范大学 一种喹嗪酮类化合物及其制备方法
JP7665619B2 (ja) 2019-12-04 2025-04-21 イドルシア・ファーマシューティカルズ・リミテッド 線維性疾患の治療に使用するためのアゼチジンlpa1受容体アンタゴニストのピルフェニドン及び/又はニンテダニブとの合剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869500A (en) * 1996-12-13 1999-02-09 Hoffmann-La Roche Inc. Pyridone compounds useful in treating Alzheimer's disease
WO2006033422A1 (ja) * 2004-09-21 2006-03-30 Japan Tobacco Inc. キノリジノン化合物、およびそのhivインテグラーゼ阻害剤としての利用
EP2252151B1 (de) * 2008-02-13 2014-05-14 Merck Sharp & Dohme Corp. Positive allosterische chinolizidinon-m1-rezeptormodulatoren

Also Published As

Publication number Publication date
EP2212322B1 (de) 2012-04-04
WO2009051715A1 (en) 2009-04-23
CA2700648A1 (en) 2009-04-23
AU2008311971A1 (en) 2009-04-23
JP2011500678A (ja) 2011-01-06
US20100222355A1 (en) 2010-09-02
EP2212322A1 (de) 2010-08-04
US8258135B2 (en) 2012-09-04

Similar Documents

Publication Publication Date Title
TN2011000209A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
EP2582676A4 (de) Positive allosterische tetrahydrochinolin-amid-m1-rezeptormodulatoren
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
MX367623B (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
EA201171197A1 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
MY153979A (en) Substituted piperidino-dihydrothienopyrimidine
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
IN2014KN01075A (de)
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
WO2009134668A3 (en) 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс
EP2073635A4 (de) Makrozyklische spiropiperidin-beta-sekretase-hemmer zur behandlung von morbus alzheimer
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
ATE477820T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten
JO2919B1 (en) Aryl methyl benzocoinazolinone M1 positive allosteric modulation receptor